Avoid common mistakes on your manuscript.
Erratum to: Support Care Cancer (2013) 21:3497–3507
DOI 10.1007/s00520-013-1932-2
The figures in the original version of this article unfortunately contained the following errors.
-
In Fig. 2b, the values presented in the bars were proportions of all patients, not proportions of patients with no/mild pain at baseline. All other information in the figure was correct. The corrected figure appears below:
-
In Fig. 4b, the correct label for proportion of subjects in the zoledronic acid group was 65.0 % (not 65.3 %) at Month 9. All other information in the figure was correct.
-
In Fig. 4c, the number of subjects was n = 2,186 for denosumab 120 mg Q4W and n = 2,155 for zoledronic acid 4 mg Q4W. The correct labels for the proportion of subjects in the zoledronic acid group were 6.1 % (not 6.0 %) at Month 2 and 9.1 % (not 9.0 %) at Month 4. All other information in the figure was correct.
-
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found at http://dx.doi.org/10.1007/s00520-013-1932-2.
Rights and permissions
About this article
Cite this article
von Moos, R., Body, JJ., Egerdie, B. et al. Erratum to: Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer 22, 2309–2310 (2014). https://doi.org/10.1007/s00520-014-2293-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-014-2293-1